6 O
ADVERSE O
REACTIONS O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
* O
Adverse O
reactions O
occurring O
in O
> O
=2 O
% O
of O
patients O
include O
nausea O
, O
vomiting O
, O
diarrhea O
, O
headache O
, O
decreased O
appetite O
, O
dizziness O
, O
abdominal O
pain O
, O
pruritus O
, O
somnolence O
, O
elevated O
transaminases O
, O
and O
elevated O
creatinine O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Paladin O
Therapeutics O
Inc O
. O
at O
1-888-550-6060 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Visceral O
Leishmaniasis O
One O
Phase O
3 O
trial O
was O
conducted O
in O
patients O
> O
= O
12 O
years O
of O
age O
in O
India O
. O

Two-hundred O
and O
ninety-nine O
( O
299 O
) O
patients O
( O
211 O
men O
and O
88 O
women O
) O
received O
oral O
IMPAVIDO O
at O
a O
target O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
( O
50 O
mg O
capsule O
once O
daily O
if O
weight O
was O
less O
than O
25 O
kg O
and O
50 O
mg O
capsule O
twice O
daily O
if O
weight O
was O
25 O
kg O
or O
greater O
) O
. O

Patients O
ranged O
between O
12 O
and O
64 O
years O
of O
age O
. O

Weight O
ranged O
between O
15 O
and O
67 O
kg O
( O
mean O
weight O
38.6 O
kg O
) O
and O
BMI O
ranged O
between O
8.2 O
and O
24 O
( O
mean O
16.1 O
) O
. O

Ninety-nine O
( O
99 O
) O
patients O
received O
1 O
mg/kg/day O
amphotericin O
B O
deoxycholate O
intravenously O
every O
other O
day O
for O
15 O
doses O
. O

A O
statistically O
significant O
higher O
percentage O
of O
men O
received O
IMPAVIDO O
compared O
to O
amphotericin O
B O
. O

Less O
than O
1 O
% O
of O
patients O
who O
received O
IMPAVIDO O
died B-NonOSE_AE
( O
2/299 O
) O
and O
no O
patient O
who O
received O
amphotericin O
B O
died B-NonOSE_AE
. O

Serious O
adverse O
reactions O
were O
reported O
in O
2 O
% O
of O
IMPAVIDO O
recipients O
( O
6/299 O
) O
and O
1 O
% O
of O
amphotericin O
B O
recipients O
( O
1/99 O
) O
. O

Approximately O
3 O
% O
of O
patients O
discontinued O
treatment O
in O
each O
treatment O
arm O
due O
to O
an O
adverse O
reaction O
. O

Serious O
adverse O
reactions O
and O
adverse O
reactions O
leading O
to O
drug O
discontinuation O
that O
were O
thought O
to O
be O
related O
or O
possibly O
related O
to O
IMPAVIDO O
included O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
and O
thrombocytopenia B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
CTCAE O
( O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
) O
Grade O
4 O
diarrhea B-OSE_Labeled_AE
( O
> O
=10 O
stools O
per O
day O
) O
and O
CTCAE O
Grade O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
( O
> O
=10x O
upper O
limit O
of O
normal O
ULN O
) O
. O

Table O
2 O
: O
Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
Visceral O
Leishmaniasis O
Patients O
Receiving O
IMPAVIDO O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
299 O
Amphotericin O
B O
DeoxycholateN O
= O
99 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
61 O
( O
20.4 O
% O
) O
6 O
( O
6.1 O
% O
) O
Vomiting B-OSE_Labeled_AE
113 O
( O
37.8 O
% O
) O
20 O
( O
20.0 O
% O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
19 O
( O
6.3 O
% O
) O
4 O
( O
4.0 O
% O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
69 O
( O
23.1 O
% O
) O
22 O
( O
22.2 O
% O
) O
In O
this O
study O
, O
creatinine B-OSE_Labeled_AE
( O
Cr O
) O
elevations I-OSE_Labeled_AE
> O
= O
1.5 O
times O
above O
baseline O
occurred O
in O
approximately O
10 O
% O
of O
IMPAVIDO O
recipients O
and O
in O
40 O
% O
of O
amphotericin O
B O
recipients O
at O
the O
end O
of O
therapy O
. O

Ten O
percent O
of O
subjects O
in O
each O
arm O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
=1.5 O
times O
above O
baseline O
at O
6 O
months O
follow O
up O
. O

No O
IMPAVIDO O
recipient O
discontinued O
therapy O
due O
to O
Cr B-NonOSE_AE
elevation I-NonOSE_AE
. O

Elevations B-OSE_Labeled_AE
of O
transaminases I-OSE_Labeled_AE
during O
therapy O
occurred O
in O
up O
to O
half O
of O
IMPAVIDO O
recipients O
and O
up O
to O
a O
third O
of O
amphotericin O
B O
recipients O
. O

The O
elevations O
were O
mild O
( O
< O
3x O
ULN O
) O
or O
moderate O
( O
3-5x O
ULN O
) O
in O
94 O
% O
and O
6 O
% O
respectively O
of O
IMPAVIDO-treated O
patients O
who O
experienced O
an O
elevation O
. O

No O
patient O
discontinued O
therapy O
due O
to O
elevations B-NonOSE_AE
in I-NonOSE_AE
transaminases I-NonOSE_AE
. O

At O
the O
end O
of O
therapy O
, O
62 O
% O
and O
2.4 O
% O
of O
IMPAVIDO O
recipients O
and O
54 O
% O
and O
2 O
% O
of O
amphotericin O
B O
recipients O
had O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
and O
< O
50,000 O
respectively O
. O

Cutaneous O
Leishmaniasis O
The O
efficacy O
of O
IMPAVIDO O
in O
the O
treatment O
of O
cutaneous B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
was O
evaluated O
in O
one O
placebo-controlled O
trial O
conducted O
in O
Colombia O
and O
Guatemala O
and O
in O
two O
comparative O
trials O
conducted O
in O
Bolivia O
and O
Brazil O
respectively O
. O

In O
the O
placebo-controlled O
trial O
, O
eighty-nine O
( O
89 O
) O
patients O
> O
=12 O
years O
of O
age O
received O
a O
target O
IMPAVIDO O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
and O
forty-four O
( O
44 O
) O
received O
placebo O
. O

In O
the O
comparative O
trials O
, O
one O
hundred O
and O
twenty O
( O
120 O
) O
patients O
> O
=12 O
years O
of O
age O
received O
a O
target O
IMPAVIDO O
dose O
of O
2.5 O
mg/kg/day O
for O
28 O
days O
and O
fifty O
eight O
( O
58 O
) O
patients O
received O
20 O
mg/kg/day O
pentavalent O
antimony O
( O
meglumine O
) O
parenterally O
for O
20 O
days O
. O

Table O
3 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
IMPAVIDO-Treated O
Patients O
> O
=12 O
Years O
of O
Age O
with O
Cutaneous O
Leishmaniasis O
in O
the O
Placebo-Controlled O
Trial O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
89 O
PlaceboN O
= O
44 O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
Motion B-OSE_Labeled_AE
Sickness I-OSE_Labeled_AE
26 O
( O
29.2 O
% O
) O
10 O
( O
22.7 O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
( O
11.2 O
% O
) O
3 O
( O
6.8 O
% O
) O
Diarrhea B-OSE_Labeled_AE
7 O
( O
7.9 O
% O
) O
2 O
( O
4.5 O
% O
) O
Nausea B-OSE_Labeled_AE
32 O
( O
35.9 O
% O
) O
5 O
( O
11.1 O
% O
) O
Vomiting B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
General B-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Malaise B-OSE_Labeled_AE
3 O
( O
3.4 O
% O
) O
1 O
( O
2.3 O
% O
) O
Pyrexia B-OSE_Labeled_AE
5 O
( O
5.6 O
% O
) O
2 O
( O
4.5 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
Headache B-OSE_Labeled_AE
25 O
( O
28.1 O
% O
) O
10 O
( O
22.7 O
% O
) O
Somnolence B-OSE_Labeled_AE
3 O
( O
3.4 O
% O
) O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
4 O
( O
4.5 O
% O
) O
0 O
Table O
4 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
of O
IMPAVIDO-Treated O
Patients O
> O
= O
12 O
Years O
of O
Age O
with O
Cutaneous O
Leishmaniasis O
in O
Two O
Comparative O
Trials O
System O
Organ O
ClassPreferred O
Term O
IMPAVIDON O
= O
120 O
MeglumineN O
= O
58 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
9 O
( O
7.5 O
% O
) O
3 O
( O
5.2 O
% O
) O
Diarrhea B-OSE_Labeled_AE
18 O
( O
15.0 O
% O
) O
3 O
( O
5.2 O
% O
) O
Nausea B-OSE_Labeled_AE
50 O
( O
41.7 O
% O
) O
3 O
( O
5.2 O
% O
) O
Vomiting B-OSE_Labeled_AE
33 O
( O
27.5 O
% O
) O
0 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Lymphangitis B-OSE_Labeled_AE
7 O
( O
5.8 O
% O
) O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
13 O
( O
10.8 O
% O
) O
4 O
( O
5.8 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
15 O
( O
12.5 O
% O
) O
4 O
( O
6.9 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
7 O
( O
5.8 O
% O
) O
0 O
In O
the O
placebo O
controlled O
trial O
, O
12/89 O
( O
13.4 O
% O
) O
IMPAVIDO O
subjects O
had O
Cr B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
of O
1.5-3 O
times O
above O
baseline O
, O
compared O
to O
2/44 O
( O
4.5 O
% O
) O
placebo O
subjects O
at O
end O
of O
therapy O
. O

In O
the O
comparative O
trial O
, O
a O
similar O
percentage O
of O
subjects O
who O
received O
IMPAVIDO O
or O
pentavalent O
antimony O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
above O
baseline O
at O
3 O
and O
6 O
months O
after O
therapy O
( O
approximately O
5 O
% O
) O
. O

Approximately O
25 O
% O
of O
IMPAVIDO O
subjects O
and O
11 O
% O
of O
pentavalent O
antimony O
subjects O
had O
Cr B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
1.5-3 O
times O
above O
baseline O
at O
the O
end O
of O
therapy O
in O
the O
two O
active O
controlled O
trials O
. O

The O
frequency O
of O
AST B-NonOSE_AE
and O
ALT O
increase I-NonOSE_AE
above O
upper O
limit O
of O
normal O
at O
end O
of O
therapy O
was O
similar O
in O
IMPAVIDO O
and O
placebo O
recipients O
( O
approximately O
5 O
% O
) O
. O

Other O
adverse O
events O
seen O
at O
< O
2 O
% O
incidence O
in O
the O
IMPAVIDO O
group O
included O
anemia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
ecthyma B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
testicular B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
pyoderma B-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
use O
of O
IMPAVIDO O
worldwide O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatics I-NonOSE_AE
Disorders I-NonOSE_AE
: O
thrombocytopenia B-OSE_Labeled_AE
, O
agranulocytosis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
melena B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
seizure B-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
ejaculate I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
, O
absent B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE

